MX2015001871A - Celulas asesinas naturales y usos de las mismas. - Google Patents

Celulas asesinas naturales y usos de las mismas.

Info

Publication number
MX2015001871A
MX2015001871A MX2015001871A MX2015001871A MX2015001871A MX 2015001871 A MX2015001871 A MX 2015001871A MX 2015001871 A MX2015001871 A MX 2015001871A MX 2015001871 A MX2015001871 A MX 2015001871A MX 2015001871 A MX2015001871 A MX 2015001871A
Authority
MX
Mexico
Prior art keywords
cell populations
methods
cells
natural killer
progenitor cell
Prior art date
Application number
MX2015001871A
Other languages
English (en)
Inventor
Robert J Hariri
Stewart Abbot
Lin Kang
Xiaokui Zhang
Vladimir Jankovic
Eric Law
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2015001871A publication Critical patent/MX2015001871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2317—Interleukin-17 (IL-17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan aquí los métodos para producir células asesinas naturales (NK) y poblaciones de células progenitoras de NK usando un método de expansión de dos etapas y diferenciación. También se proporcionan aquí los métodos para producir poblaciones de células NK y poblaciones de células progenitoras de NK usando un método de expansión de tres etapas y diferenciación. También se proporcionan aquí los métodos para suprimir la proliferación de células tumorales usando células NK, las poblaciones de células NK y las poblaciones de células progenitoras de NK producidas por los métodos descritos aquí, así como los métodos de tratamiento de individuos que tienen cáncer o una infección viral, que comprende administrar las células NK, las poblaciones de células NK, y las poblaciones de células progenitoras de NK producidas por los métodos descritos aquí a un individuo que tiene el cáncer o infección viral.
MX2015001871A 2012-08-13 2013-08-13 Celulas asesinas naturales y usos de las mismas. MX2015001871A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682706P 2012-08-13 2012-08-13
US201361799211P 2013-03-15 2013-03-15
PCT/US2013/054677 WO2014028453A2 (en) 2012-08-13 2013-08-13 Natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
MX2015001871A true MX2015001871A (es) 2015-09-21

Family

ID=50101590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001871A MX2015001871A (es) 2012-08-13 2013-08-13 Celulas asesinas naturales y usos de las mismas.

Country Status (12)

Country Link
US (1) US20150225697A1 (es)
EP (2) EP3722416A1 (es)
JP (4) JP2015526088A (es)
KR (3) KR20150063374A (es)
CN (2) CN105008516A (es)
AU (3) AU2013302853A1 (es)
BR (1) BR112015003149A2 (es)
CA (1) CA2881792C (es)
HK (1) HK1211620A1 (es)
MX (1) MX2015001871A (es)
RU (2) RU2015108761A (es)
WO (1) WO2014028453A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN111643663A (zh) 2013-03-15 2020-09-11 细胞基因公司 修饰的t淋巴细胞
JP2016537362A (ja) 2013-11-15 2016-12-01 アントフロゲネシス コーポレーション ヒト胎盤灌流液細胞、その亜集団を含む組成物、およびそれらの使用
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
EA201791443A1 (ru) * 2014-12-31 2018-01-31 Антродженезис Корпорейшн Естественные киллерные клетки и их применения
WO2016162827A1 (en) * 2015-04-09 2016-10-13 Universita' Degli Studi Di Genova Population of human lymphoid precursors, method for their identification and uses thereof
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
US20200016198A1 (en) * 2015-11-05 2020-01-16 Glycostem Therapeutics B.V. Composition for use in immunotherapy
CN106701677A (zh) * 2015-11-18 2017-05-24 深圳爱生再生医学科技有限公司 Nk细胞的体外扩增培养方法
US20190037831A1 (en) * 2016-02-01 2019-02-07 Green Cross Lab Cell Corporation Medium composition for cryopreservation of cell and use thereof
SG11201809858RA (en) * 2016-05-07 2018-12-28 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
KR101866827B1 (ko) * 2016-09-28 2018-07-19 한국원자력의학원 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물
RU2021134402A (ru) 2016-11-14 2022-01-14 Пэан Байотекнолоджи Инк. Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку
WO2018110159A1 (ja) * 2016-12-14 2018-06-21 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
EA201991607A1 (ru) * 2016-12-30 2020-01-24 Селулэрити, Инк. Генетически модифицированные клетки-натуральные киллеры
US20200048610A1 (en) * 2017-03-27 2020-02-13 INSERM (Institute National de la Santé et de la Recherche Médicale) New method to obtain lymphoid progenitors
CN113061577A (zh) * 2017-09-05 2021-07-02 四川新生命干细胞科技股份有限公司 一种高纯度nk细胞的分离培养方法
CA3077325A1 (en) * 2017-09-28 2019-04-04 Celularity Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
CA3076456A1 (en) 2017-10-02 2019-04-11 Gamida-Cell Ltd. Expansion and use of expanded nk cell fractions
CN107904175B (zh) * 2017-12-29 2018-09-25 广州沙艾生物科技有限公司 用于免疫细胞的诱导扩增的培养箱
EP3820994A1 (en) 2018-07-10 2021-05-19 Nantkwest, Inc. Generating cik nkt cells from cord blood
CN109337870B (zh) * 2018-12-24 2020-07-03 广东暨德康民生物科技有限责任公司 人Vγ9Vδ2T细胞扩增方法与培养基
KR102032384B1 (ko) * 2019-03-05 2019-11-08 주식회사 온코인사이트 제대혈 단핵세포에서의 자연살해세포의 제조 방법
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
JP2022529280A (ja) * 2019-04-17 2022-06-20 チャ バイオテック カンパニー リミテッド 抗癌活性が増大されたナチュラルキラー細胞、及びその免疫治療用途
KR102233660B1 (ko) * 2019-05-15 2021-03-30 (주)포에버엔케이 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트
IT201900023922A1 (it) * 2019-12-13 2021-06-13 Univ Degli Studi Genova Popolazione cellulare progenitrice CD56-CD16+PerfnegCD7- e progenie cellulare NK CD94/NKG2C+KIR+CD57+ originata da detta popolazione cellulare CD56-CD16+PerfnegCD7-, loro ottenimento e loro usi
WO2021178890A1 (en) 2020-03-06 2021-09-10 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法
CN112029722A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种nk细胞培养基及其应用
CN112266900A (zh) * 2020-10-30 2021-01-26 广东康盾生物工程技术有限公司 一种car-nk细胞的培养方法
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN113416701B (zh) * 2021-07-28 2023-05-09 新疆西部赛澳生物科技有限责任公司 一种nk细胞培养基及培养方法
WO2023011114A1 (zh) * 2021-08-06 2023-02-09 中国科学院动物研究所 一种ric细胞及其制备方法和应用
CN113801846B (zh) * 2021-09-22 2024-06-04 南京艾尔普再生医学科技有限公司 一种从人诱导多能干细胞分化为自然杀伤细胞的方法
CN114891856A (zh) * 2022-05-16 2022-08-12 武汉科技大学 大队列样本单细胞富集和混样建库测序方法
CN114736859B (zh) * 2022-06-13 2022-08-19 广东先康达生物科技有限公司 一种脐带血nk细胞的培养液及培养方法
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
US20240279607A1 (en) * 2023-02-17 2024-08-22 FullHope Biomedical Co., Ltd. Pharmaceutical composition comprising modified natural killer cells and antigen-specific t cells, manufacturing method thereof, and method of using the same
CN117603809A (zh) * 2023-12-06 2024-02-27 威海紫光科技园有限公司 一种应用于nk细胞制备过程中复苏的温度控制方法及系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2002046373A1 (en) 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CN108559725A (zh) 2005-12-29 2018-09-21 人类起源公司 胎盘干细胞群
KR20080097190A (ko) 2005-12-29 2008-11-04 안트로제네시스 코포레이션 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
EP2142642B1 (en) * 2007-03-27 2017-08-09 IPD-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
MX342995B (es) * 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
WO2012065156A2 (en) * 2010-11-13 2012-05-18 University Of Florida Research Foundation, Inc. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
ES2856825T3 (es) * 2011-03-18 2021-09-28 Glycostem Therapeutics B V Generación de células NK y progenitores de células NK

Also Published As

Publication number Publication date
WO2014028453A3 (en) 2014-10-09
CN105008516A (zh) 2015-10-28
RU2019124982A (ru) 2019-09-02
CA2881792A1 (en) 2014-02-20
JP2018183161A (ja) 2018-11-22
HK1211620A1 (en) 2016-05-27
CA2881792C (en) 2024-02-27
KR20150063374A (ko) 2015-06-09
JP2020188782A (ja) 2020-11-26
EP3722416A1 (en) 2020-10-14
AU2013302853A1 (en) 2015-03-05
US20150225697A1 (en) 2015-08-13
AU2022200976A1 (en) 2022-03-03
RU2015108761A (ru) 2016-10-10
JP2015526088A (ja) 2015-09-10
EP2882847A4 (en) 2016-03-23
BR112015003149A2 (pt) 2017-08-08
KR20210076150A (ko) 2021-06-23
JP2023036639A (ja) 2023-03-14
WO2014028453A2 (en) 2014-02-20
AU2019204020A1 (en) 2019-06-27
CN114134113A (zh) 2022-03-04
EP2882847A2 (en) 2015-06-17
KR20220166873A (ko) 2022-12-19

Similar Documents

Publication Publication Date Title
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
MX342995B (es) Métodos de generar células asesinas naturales.
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
MX2018004146A (es) Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t.
MX2020000369A (es) Metodos biologicos para preparar terpenos.
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
SG178991A1 (en) Anti-gitr antibodies
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
EP2794859A4 (en) METHOD FOR PRODUCING NATURAL KILLER CELLS, NATURAL KILLER CELLS PRODUCED THEREFOR, AND COMPOSITION FOR TREATING CANCERS AND INFECTIOUS DISEASES CONTAINING THE SAME
MX2015005797A (es) Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica.
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
MX2021009554A (es) Produccion de virus en cultivos celulares.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
MX2013004353A (es) Produccion recombinante de n-propanol e isopropanol.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
IN2014DN06104A (es)
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.